Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness by Lékó, András Hugó et al.
1Scientific RepoRts | 7: 3396  | DOI:10.1038/s41598-017-03645-5
www.nature.com/scientificreports
Insulin-like growth factor I and its 
binding protein-3 are regulators 
of lactation and maternal 
responsiveness
András H. Lékó1,2, Melinda Cservenák1,2, Éva Rebeka Szabó1, János Hanics3, Alán Alpár3,4 & 
Árpád Dobolyi  1,2,5
Adaptation to motherhood includes maternal behaviour and lactation during the postpartum period. 
The major organizing centres of maternal behaviour and lactation are located in the hypothalamic 
medial preoptic area (MPOA) and the arcuate nucleus, respectively. Insulin-like growth factor I (IGF-I) 
is an effector of the growth hormone axis; however, its function in the brain is largely unexplored. We 
identified increased maternal IGF binding protein-3 (IGFBP-3) expression in preoptic rat microarray data 
and confirmed it by RT-PCR. In situ hybridization histochemistry showed markedly elevated IGFBP-3 
expression in the MPOA and the arcuate nucleus in rat dams. Prolonged intracerebroventricular 
injection of IGF-I or antagonism of brain IGFBP-3 with an inhibitor (NBI-31772) using osmotic 
minipumps increased pup retrieval time, suggesting reduced maternal motivation. Suckling-induced 
prolactin release and pup weight gain were also suppressed by IGF-I, suggesting reduced lactation. 
In addition, IGF-I-induced tyrosine hydroxylase expression and its specific phosphorylation in 
tuberoinfundibular dopaminergic neurons suppress prolactin secretion. Thus, IGF-I may inhibit both 
behavioural and lactational alterations in mothers. Neurons in the MPOA and arcuate nuclei express 
IGFBP-3 during the postpartum period to neutralize IGF-I effects. IGFBP-3 can prevent the blockade 
of maternal behaviour and lactation exerted by IGF-I, suggesting a novel modulatory mechanism 
underlying the behavioural and hormonal effects during central maternal adaptations.
Postpartum physiological and behavioural changes are important parts of mammalian reproduction, and they 
can be investigated using the rat as an animal model. Non-maternal females do not care about pups or even attack 
them, while mothers demonstrate well-defined maternal behaviours, e.g., nest building, pup retrieval to the nest, 
nursing, and decreased anxiety, in addition to lactation. These marked changes are the consequences of maternal 
adaptation of the central nervous system. Lactation is known to be driven by prolactin secreted from the pitui-
tary1. Prolactin secretion is controlled by the inhibitory effect of dopamine produced by the tuberoinfundibular 
dopamine (TIDA) neurons. These neurons are located in the arcuate nucleus and project to the external zone of 
the median eminence and excrete dopamine into the pituitary portal blood vessels2. The modulators of prolactin 
release are known to affect the TIDA neurons; however, the major intrinsic regulators of the switch in the mode 
of these neurons, which permits the dramatically increased prolactin secretion required for lactation, need to be 
elucidated2, 3.
Prolactin and other hormones contribute to the initiation of maternal behaviours4, 5 but are not required for it6, 7. 
Rather, maternal behaviour is controlled by a complex neuronal network8, 9 in which the medial preoptic area 
(MPOA) plays a central role10. The density of active neurons is dramatically induced in the MPOA of parenting 
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females9. Furthermore, lesions of the MPOA abolish the nest building and retrieving components of maternal 
behaviour in lactating females11–13, while electrical and optogenetic stimulation of this area enhances maternal 
responsiveness8, 9, 14. Although the molecular mechanisms of maternal motivation are unknown, gene expression 
alterations have been hypothesized to be involved15. Previously, we carried out a microarray study of the preoptic 
area and identified amylin as a maternally induced neuropeptide16. We validated and functionally characterized 
amylin in mother rats17 but did not evaluate other genes with altered mRNA expression. In the present study, we 
identified significantly altered genes in our previous microarray study16, compared them with previous microar-
ray data18, and investigated the maternal function of a gene altered in both studies, insulin-like growth factor 
binding protein-3 (IGFBP-3).
Insulin-like growth factor binding protein-3 (IGFBP-3) binds insulin-like growth factor-I (IGF-I) in the 
plasma and extracellular space. Although 6 other IGFBPs exist, IGFBP-3 is the major carrier of IGF and binds the 
majority of IGF-I in circulation19. By binding IGF with high affinity in a functionally inactive complex, IGFBP-3 
can inhibit the effects of IGF-I. IGFBP-3 overexpressing mice show intrauterine and postnatal growth retarda-
tion, confirming the IGF-neutralizing role of IGFBP-320. In addition, IGFBP-3 may also have IGF-independent 
effects21–23. IGFBP-3 is normally expressed in the adult central nervous system (CNS) at a low level, mainly in 
non-neuronal cells, and the effects of IGFBP-3 on the CNS are largely unknown24–28.
IGF-I is mainly produced by the liver and is related to the growth hormone axis. IGF-I is released into the 
circulation and can reach the central nervous system via the blood-brain-barrier and blood-cerebrospinal fluid 
barrier. In addition, IGF-I is also expressed in the brain. The actions of IGF-1 are mediated by a cell surface recep-
tor, type 1 IGF receptor (IGF-1R), which is the major transducer of IGF signals29. IGF-1 signalling in the brain 
supports neuronal survival and neuroprotection during the development of the CNS and in adults following brain 
injuries30. In the hypothalamus, IGF-I can feedback to the growth hormone axis but may also affect reproductive 
neuroendocrine functions31–33. However, the effects of IGF-I on lactation and prolactin release, an important 
aspect of reproduction, have not been investigated.
In this study, we first established that the expression of IGFBP-3 was significantly elevated in lactating rat 
mothers compared with that in mothers whose pups were taken away right after parturition (pup-deprived moth-
ers). Second, we revealed the involvement of IGFBP-3 in the control of maternal behaviour with an IGFBP-3 
antagonist. We also showed that the effect of IGF-I treatment was similar that of the IGFBP-3 antagonist. Third, 
we described the expression pattern of IGFBP-3 in the hypothalamus and identified two regions, the medial 
preoptic area and the arcuate nucleus, where its expression was markedly elevated in rat dams. Then, we demon-
strated that the IGF-IGFBP-3 system regulates suckling-induced prolactin release. Furthermore, we identified the 
underlying mechanisms of the effects of IGF-I on prolactin-regulating tuberoinfundibular dopaminergic neurons 
both in vivo and in vitro.
Results
Genes with altered mRNA expression in the preoptic area of rat dams. To determine the genes 
that show altered expression in mothers, we re-evaluated our previous microarray study in the preoptic area of 
mother rats16 and compared the results of this analysis with a recent microarray study18. We identified 21 genes 
with highly significant differences in expression levels between the maternal and non-maternal groups (p < 0.007) 
in our previous experiment (Table 1). Islet amyloid polypeptide (amylin) exhibited the greatest elevation in moth-
ers compared with that in pup-deprived controls and has been identified as a novel neuropeptide with maternal 
functions in the rat17. The expression levels of 5 other genes (ELL-associated factor 2, dopamine receptor 4, insu-
lin-like growth factor binding protein 3, follistatin, and selectin) were 2–4 times higher in rat dams than those in 
the pup-deprived control group. Of these genes, insulin-like growth factor binding protein-3 (IGFBP-3) was also 
up-regulated in the study of Driessen et al. 2014. Therefore, we choose to further investigate the maternal function 
of this protein.
RT-PCR and in situ hybridization histochemistry validation of the induction of IGFBP-3 in the 
preoptic area of rat mothers. Preoptic samples were dissected from 9 lactating and 8 pup-deprived 
females for RT-PCR validation of the microarray results (Fig. 1a). We revealed higher IGFBP-3 mRNA levels 
in the preoptic area of lactating dams compared with those in mothers deprived of their pups (Fig. 1b) while 
there was no difference in the level of GAPDH mRNA between the 2 groups. We used IGFBP-3 in situ hybrid-
ization histochemistry to determine its distribution in the preoptic area (Fig. 1c,d). We used two different, 
non-overlapping in situ hybridization probes, which showed the same distribution pattern of IGFBP-3 expression 
and confirmed their specificity. The hybridization signal was present in the medial preoptic area, especially in the 
medial preoptic nucleus. The quantification of the autoradiography signal revealed an elevated level of IGFBP-3 
in lactating mother rats (Fig. 1e).
Antagonism of IGFBP-3 and IGF-I suppresses pup retrieval behaviour. To assess the involvement 
of IGFBP-3 in maternal motivation, IGF-I and NBI-31772, a non-peptide ligand inhibitor of IGFBP-3, were con-
tinuously administered intracerebroventricularly (i.c.v.) via osmotic minipumps implanted in rat mothers on 
the 2nd postpartum day. The first group of mothers was treated with IGF-I, while their control group (n = 10) 
received ACSF. Then, NBI-31772 dissolved in 1% dimethyl sulfoxide (DMSO) in ACSF was administered i.c.v. to 
another group. Their control group received 1% DMSO in ACSF i.c.v. We performed a pup-retrieval test on the 
6th day postpartum and found a markedly elevated pup retrieval time in the IGF-I- and NBI-31772-treated groups 
of mothers (Fig. 2a,b). These mothers took 4–5 more times to carry the first pup back to the nest. The time to 
retrieve the last pup was 3.7 times longer for the IGF-treated mothers than that for the ACSF group, but there was 
no difference between NBI-31772 and its control group. Starting on the 4th postpartum day, we also investigated 
5 elements of undisturbed maternal behaviour (high kyphosis, licking/grooming, prone nursing, supine nursing, 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 3396  | DOI:10.1038/s41598-017-03645-5
mother out of the nest) for 5 days, 3 × 1 hour/day, 20 observations/hour and did not find any significant difference 
between the groups (Table 2). To examine the motility and anxiety of the mothers, we carried out an elevated 
plus maze test on the 7th postpartum day (Table 2). We did not find any difference between the groups in the total 
number of entries, a marker of motility. IGFBP-3 antagonism and IGF-I administration did not cause changes in 
the open arm entry percentage, a marker of anxiety.
IGFBP-3 mRNA expression is markedly elevated in the arcuate nucleus of lactating rat moth-
ers. In situ hybridization histochemistry revealed that the expression of IGFBP-3 is not confined to the pre-
optic area within the hypothalamus; the dorsomedial subdivision of the arcuate nucleus and the paraventricular 
hypothalamic nucleus (PVN) also contained IGFBP-3 mRNA (Fig. 3a–c). The quantification of the in situ hybrid-
ization histochemistry signal revealed that IGFBP-3 had an approximately 3-fold increase in the expression level 
in the dorsomedial subdivision of the arcuate nucleus in mother rats compared with that in pup-deprived controls 
(n = 6 − 6; Fig. 3d1). In contrast, there was no maternal increase in the expression level of IGFBP-3 in the PVN.
IGFBP-3 is expressed in tuberoinfundibular dopaminergic neurons in the arcuate nucleus of 
lactating mother rats. The location of IGFBP-3-expressing neurons was similar to that of dopaminergic 
neurons in the dorsomedial subdivision of the arcuate nucleus in lactating dams. Tyrosine hydroxylase (TH) is 
the main immunohistochemical marker of dopaminergic neurons in the arcuate nucleus, which regulates the 
secretion of prolactin from the pituitary. Therefore, we combined IGFBP-3 in situ hybridization histochem-
istry with TH immunohistochemistry to determine if dopaminergic neurons express IGFBP-3 mRNA in the 
arcuate nucleus (Fig. 4). We found a high degree of co-localization; 67.3% of tuberoinfundibular dopaminergic 
(TIDA) neurons contained IGFBP-3 and 85.9% of IGFBP-3 neurons contained TH immunoreactivity, suggest-
ing that in the arcuate nucleus of lactating mothers (n = 5), IGFBP-3 mRNA expression is markedly elevated in 
TH-immunoreactive dopaminergic neurons.
IGF-I lowers suckling-induced prolactin release. TIDA neurons play a key role in the hypothalamic 
control of prolactin secretion. Therefore, we investigated whether maternally elevated IGFBP-3 plays a role in this 
regulation by sequestering IGF-I in a functionally inactive complex. IGF-I and ACSF, as a control, were admin-
istered i.c.v. to rat mothers via osmotic minipumps in the same composition and concentration as described 
above. The serum prolactin levels induced by suckling were measured on the 14th postpartum day. Before the 
p
Fold 
change Name of gene product RefSeq
UniGene 
code
0.00001 25.732 islet amyloid polypeptide NM_012586 Rn.11394
0.00015 0.466 similar to RNA binding motif protein 3 XM_001063211 Rn.18057
0.00016 0.422 aldo-keto reductase family 1, member B7 NM_053781 Rn.32702
0.00031 0.469 S100 calcium-binding protein A4 NM_012618 Rn.504
0.00034 0.442 microtubule-associated protein tau NM_017212 Rn.2455
0.00045 0.415 similar to macrophage scavenger receptor 2 XM_001067252 Rn.76819
0.00050 0.438 procollagen, type III, alpha 1 NM_032085 Rn.3247
0.00052 0.465 similar to aldo-keto reductase family 1, member C19 XM_001062695 Rn.16371
0.00052 0.392 similar to ectonucleotide pyrophosphatase/phosphodiesterase 6 XM_001056025 Rn.8484
0.00059 0.359 KiSS-1 metastasis-suppressor NM_181692 Rn.66008
0.00060 0.490 hypothetical protein XM_001066258 Rn.139226
0.00069 0.367 calbindin 3, (vitamin D-dependent calcium binding protein) NM_012521 Rn.9974
0.00084 0.373 asialoglycoprotein receptor 1 (hepatic lectin) NM_012503 Rn.44300
0.00144 0.401 similar to procollagen, type I, alpha 1 XM_001081230 Rn.2953
0.00200 2.653 ELL associated factor 2 NM_172047 Rn.20681
0.00207 3.720 dopamine receptor 4 NM_012944 Rn.10159
0.00277 0.415
similar to Paired mesoderm homeobox 
protein 2 (PRX-2) (Paired-related 
homeobox protein 2)
XM_001079701 Rn.93004
0.00281 2.186 insulin-like growth factor binding protein 3 NM_012588 Rn.26369
0.00537 2.473 follistatin NM_012561 Rn.162557
0.00546 0.439 ring finger protein 141 NM_001001800 Rn.127990
0.00685 2.152 selectin, endothelial cell NM_138879 Rn.10359
Table 1. Microarray data from lactating mother rats compared to non-maternal previous mothers whose pups 
were taken away right after delivery (pup-deprived mothers). The listed 21 genes showed highly significant 
(p < 0.007) difference between the two groups in our microarray study (n = 4 rat for each group)16.
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pups were removed for 4 h, the prolactin concentrations were 166.3 ± 30.3 and 103.96 ± 22.35 ng/ml in the ACSF- 
and IGF-I-treated groups, respectively. The plasma prolactin concentration was reduced to basal levels by the 
end of a subsequent 4-hour separation period (Fig. 5). The pups were then returned to the mother at 0 min, 
which led to almost immediate nursing and suckling and in turn resulted in dramatically elevated serum prol-
actin levels (Fig. 5). We performed a two-way repeated measures ANOVA to examine if IGF-I has an effect on 
suckling-induced prolactin release. The effect of treatment was significant (p < 0.001, F = 33.85), and the inter-
action of time and treatment as well (p < 0.01, F = 3.34). Suckling induced the prolactin release significantly 
in both groups (effect of time: p < 0.001, F = 17.69). We conducted Newman-Keuls post hoc test to assess the 
specific times, at which a difference was found between ACSF and IGF-I treated groups. At 15, 30 and 60 min 
after the pups were returned, the prolactin level was significantly reduced by IGF-I with the following p values: 
p = 0.0013, p = 0.0002, and p = 0.0167, respectively. These results indicate that prolonged administration of IGF-I 
can suppress the suckling-induced prolactin release in mother rats. The reduced prolactin secretion was also 
reflected by the reduced weight gain of the litters, which was 11.1 ± 1.4 g for the ACSF-treated and 7.5 ± 1.8 g for 
the IGF-I-treated mothers (p = 0.013).
IGF-I administration induces TH expression in the arcuate nucleus of mother rats in vivo. We 
addressed the potential mechanisms involved in the actions of IGF-I in the suppression of prolactin release. 
TH, which is the rate-limiting enzyme in dopamine synthesis, regulates dopamine levels in dopaminergic cells. 
Therefore, we used in situ hybridization histochemistry to determine the expression level of TH mRNA in TIDA 
neurons (A12 cell group), which play a crucial role in the regulation of pituitary prolactin secretion, and in dopa-
minergic cells in the zona incerta (A13 cell group), which do not participate in the control of prolactin secretion. 
TH expression was quantified using densitometry in the brains of IGF-I- and ACSF-treated rat dams. A twofold 
elevation in TH mRNA expression was found in IGF-I-treated mothers in the arcuate nucleus compared with 
that in the control group (Fig. 6). By contrast, there was no significant difference between the two groups in the 
zona incerta (Fig. 6).
Figure 1. Induction of IGFBP-3 in the preoptic area of lactating rat mothers. (a) Schematic figures show the 
dissected area, which was used for RT-PCR validation of the microarray data. The rostral and caudal borders 
of the dissected area were at +0.6 and −1.4 mm from the bregma, respectively. A dorsal horizontal cut was 
made immediately above the level of the anterior commissure, and the lateral borders were cut 2 mm lateral 
to the midline. (b) IGFBP-3 mRNA level was 3 times higher in the preoptic area of rat dams (n = 9) compared 
with that in the preoptic area of pup-deprived controls (n = 8; *: p < 0.05). Data are presented as the ratio 
to GAPDH mRNA levels as the mean values ± SEM. (c,d) Dark-field photomicrographs of IGFBP-3 in situ 
hybridization histochemistry show that the IGFBP-3 mRNA hybridization signal (white) was elevated in rat 
dams (c) compared with that in pup-deprived rat mothers (d) in the medial preoptic area (MPA) and the medial 
preoptic nucleus (MPN). (e) Densitometric analysis shows that the IGFBP-3 labelling intensity is significantly 
elevated in the MPA of lactating mothers compared with that in pup-deprived controls (n = 6–6; ***p < 0.001, 
p = 0.00002). Density is expressed in arbitrary units (AU). The results are presented as the mean values ± SEM. 
Further abbreviations: 3 V – third ventricle; ac – anterior commissure; AHA – anterior hypothalamic area; CP – 
caudate putamen; DB – diagonal band; f – fornix; och – optic chiasm. Scale bar = 400 µm.
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IGF-I treatment enhances TH expression and increases site-specific phosphorylation in 
vitro. Mediobasal hypothalamic primary cell cultures were prepared from newborn rats and incubated for 
4 days with IGF-I-containing (12.5 µg/ml) or control medium. IGF-I administration significantly (p = 0.048) 
enhanced the TH mRNA expression – measured by real time RT-PCR – compared with that in the control cul-
tures, which were treated with control medium (Fig. 7a).
Another group of hypothalamic cell cultures was grown in control medium for 4 days, and on the 5th day, half 
of them were incubated in IGF-I-containing medium for 30 min at the same concentration as described above. 
Using Western blotting with phosphorylation-site specific antibodies, we determined that IGF-I stimulated a sig-
nificant increase in the phosphorylation of the Ser 31 residue when compared with that in cells incubated under 
basal conditions. In contrast, IGF-I did not enhance the phosphorylation of the Ser 40 residue (Fig. 7b).
Discussion
We have now evaluated our previous microarray study, which was focused on a single gene16, and identified 5 
additional genes with highly significant and over 2-fold increases in mother rats. The results were compared with 
those of a similar microarray study18 in which 27 maternally induced genes involved in CNS development were 
identified in mice. There are some differences between the designs of the two studies, including rats vs. mice, post-
partum day 9 vs. 7, non-maternal females vs. virgin females as the control group, and dissected tissue from the 
whole preoptic area vs. only the medial preoptic area. Despite these differences, we identified a gene, insulin-like 
growth factor binding protein-3 (IGFBP-3), which was elevated in mother rats in both studies. Because of the high 
rate of false positive data in microarray experiments34, we measured the mRNA level of IGFBP-3 in rat dams and 
Figure 2. Antagonism of IGFBP-3 and IGF-I administration markedly lengthens the latency to retrieve 
pups. (a,b) Mothers were treated from the 2nd postpartum day intracerebroventricularly (i.c.v.) via osmotic 
minipumps connected with brain infusion kits with artificial cerebrospinal fluid (ACSF) (n = 10) or dimethyl 
sulfoxide (DMSO) (n = 8) dissolved in ACSF as controls and with a nonpeptide IGFBP-3 ligand inhibitor, 
NBI-31772 (1.66 µg/µl in DMSO ACSF; n = 8) or IGF-I (4 µg/µl in ACSF; n = 10). Both treatments significantly 
increased the time to carry the first pup back to the nest (**p < 0.01, p = 0.0017 and 0.0037, respectively). 
IGF-I administration also increases the time to retrieve the last pup (***p < 0.001, p = 0.0008). The results are 
presented as the mean values ± SEM.
ACSF IGF DMSO NBI-31772
total number of entries 10.57 ± 2.01 11.4 ± 1.65 12 ± 1.78 11 ± 1.58
open arm entries (%) 46.33 ± 3.24 36.36 ± 6 46.66 ± 4.51 45.22 ± 5.07
high kyphosis (%) 26 ± 2.34 21.43 ± 2.22 23.8 ± 1.98 23 ± 2.68
licking/grooming (%) 7.03 ± 0.54 5.13 ± 0.73 6 ± 0.84 7.96 ± 1.43
prone nursing (%) 21.14 ± 8.15 21.71 ± 7.91 24.62 ± 15.46 20.22 ± 5.24
supine nursing (%) 5.23 ± 4.17 7.17 ± 5.4 7.76 ± 7.91 6.8 ± 4.56
out of the nest (%) 42 ± 3.08 45.71 ± 3.1 39 ± 5.08 44.9 ± 4.72
Table 2. Antagonism of IGFBP-3 does not change undisturbed maternal behaviour and elevated plus-maze test 
performance of rat dams. The ratio of 5 examined elements of maternal behaviours is shown in the table. In the 
elevated plus maze test, unchanged total number of entries suggest unaltered motility of the animals while the 
lack of significantly changed open arm entry frequency suggest unaltered anxiety-like behaviour.
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pup-deprived controls with 2 independent methods, RT-PCR and in situ hybridization histochemistry, as IGFBP-3 
induction has not been validated in the previous studies. Both methods validated the increased IGFBP-3 expres-
sion level in the preoptic area in lactating rat dams. The confirmed maternal elevation in IGFBP-3 expression and 
its distribution in the region of the preoptic area involved in maternal behaviour, the medial preoptic area35, sug-
gest its involvement in the control of maternal behaviour. There are several different neuronal populations in this 
area that contribute to this regulation network, including galanin-, amylin- or melanin-concentrating hormone 
(MCH)-expressing neurons8, 17, 36. Of these populations, the distribution of IGFBP-3 in the MPOA is similar 
to the expression pattern of MCH. The expression of MCH increases gradually until the weaning of pups36, 37  
Figure 3. IGFBP-3 mRNA expression is present in the hypothalamus. (a,b) Dark-field photomicrographs of 
IGFBP-3 in situ hybridization histochemistry show that the IGFBP-3 mRNA hybridization signal (white) is 
present in the hypothalamic paraventricular nucleus (PVN) and the arcuate nucleus. In the PVN, the signal 
intensity appears similar between mothers (a1) and pup-deprived controls (a2). In contrast, IGFBP-3 expression 
seems more abundant in lactating mothers (b1) than in pup-deprived rat mothers (b2) in the arcuate nucleus  
(c) High magnification bright-field photomicrographs show the corresponding framed areas in b to 
demonstrate the increased number of individual autoradiography grains (black dots) in the dorsomedial 
subdivision of the arcuate nucleus in lactating mothers. (d1) Densitometric analysis reveals that the IGFBP-3 
labelling intensity is significantly elevated in the arcuate nucleus of lactating mothers (***p < 0.001). (d2) There 
were no significant differences between lactating and pup-deprived females in the PVN. Density is expressed in 
arbitrary units (AU). The results are presented as the mean values ± SEM. Further abbreviations: Arc – arcuate 
nucleus, 3 V – third ventricle. Scale bars = 800 µm in (a,b) and 200 µm in (c).
www.nature.com/scientificreports/
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and has been suggested to be involved in the termination of maternal responsiveness during the late postpartum 
period38.
Apart from the preoptic area, IGFBP-3 expression was also detected in other hypothalamic sites by in situ 
hybridization histochemistry, suggesting additional functions. The role of IGFBP-3 in the PVN is unlikely to be 
Figure 4. IGFBP-3 expression co-localizes with tyrosine-hydroxylase (TH) in the arcuate nucleus. The 
combination of IGFBP-3 in situ hybridization histochemistry (black dots) and TH immunohistochemistry 
(brown cells) shows that TH-positive cells in the dorsomedial subdivision of the arcuate nucleus express 
IGFBP-3 mRNA in lactating rat dams. Abbreviations include 3 V – third ventricle, dmArc – dorsomedial 
arcuate nuclei, em – median eminence. Scale bar = 400 µm for A, and 100 µm for B.
Figure 5. IGF-I administration significantly suppresses suckling-induced prolactin release. Blood was taken 
first at 8.00 AM, before the removal of the pups from their mother; second, right before the pups were returned 
after a 4-hour isolation period; the 3rd, 4th, 5th and 6th blood samples were obtained at 5, 15, 30 and 60 min after 
the pups were returned (start of suckling). The diagram shows the serum prolactin levels in mothers during 
the pup isolation-suckling protocol. The animals treated with IGF-I are shown in red (n = 7), while the ACSF-
treated rats are shown in blue (n = 8). The x-axis shows time in a nonlinear fashion. Below the x-axis, the 
periods of pup separation and suckling are indicated with grey arrows. During the initial time point, before 
the isolation period, the plasma prolactin levels in the two groups of animals did not differ significantly as 
determined by Newman-Keuls post hoc test, even though a clear trend is visible for reduced levels in IGF-I 
treated animals. Without the litter, the prolactin levels dropped to an equally low basal value in both groups. 
Then, the plasma prolactin levels rose during suckling, but IGF-I administration significantly attenuated the 
elevation in plasma prolactin levels at 15, 30 and 60 min after the pups were returned (***p < 0.001; **p < 0.01, 
t = 4.124, t = 4.804 and t = 3.322, respectively). The results are presented as the mean values ± SEM.
www.nature.com/scientificreports/
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related to maternal modifications as the expression level did not change in mothers. This finding also suggests that 
the induction of IGFBP-3 may be specific to certain cell types. Indeed, IGFBP-3 was induced in the dorsomedial 
subdivision of the arcuate nucleus, specifically in TH-positive dopaminergic cells. These cells are known to regu-
late prolactin release from the pituitary39, which suggests an additional role for IGFBP-3 in lactation. The IGFBP-3 
distribution data in the hypothalamus have not been reported before. A previous study focusing on the effect of 
hypoxia on IGFBP-3 reported its expression in the brain but described only cortical and thalamic locations40.
The distribution of IGFBP-3 suggests that it may participate in the control of maternal behaviours and lac-
tation. IGFBP-3 binds IGF-I with high affinity, thereby reducing the level of bioavailable IGF-I. To examine the 
role of IGFBP-3 in the regulation of maternal behaviours and lactation, we inhibited this IGF-sequestering effect 
with continuous and prolonged i.c.v. infusion of either IGF-I or an IGFBP ligand-binding inhibitor, NBI-3177241. 
These infusions presumably increased the hypothalamic bioavailability of IGF-I. Although peripherally adminis-
tered IGF-I reduces the brain level of IGF-I42, we used continuous central infusions to ensure its permanently high 
bioavailability in the hypothalamus. To administer the drugs, we used osmotic minipumps with a continuous 0.5 
μl/hour flow rate for a maximum of 14 days. Another reason why we preferred prolonged IGFBP-3 inhibition is 
that slow, neuroplastic effects can also be detected. For example, acute IGF-I and NBI-31772 administration have 
anxiolytic and antidepressant-like effects41, 43, while their prolonged administration can affect neuronal plasticity 
and neural survival in dopaminergic neurons44, 45. We did not detect the anxiolytic effects of these agents follow-
ing their long-term presence as neither affected the number of open arm entries in the elevated plus-maze test, a 
marker of anxiety-like behaviour.
The effect of IGFBP-3 inhibition in the brain on maternal behaviour was examined. The mothers showed 
several aspects of normal behaviour, demonstrating that they can perform maternal behaviours. However, we 
measured an increased latency to carry the first pup and the last pup into the nest following the sequestration of 
Figure 6. I.c.v. IGF-I administration enhanced the expression of TH in the arcuate nucleus. (a,b) The 
brains of IGF-I- and ACSF-treated rat mothers (n = 4 in both groups) were used for in situ hybridization 
histochemistry. Dark-field photomicrographs show that TH mRNA expression (white dots) was abundant 
in the zona incerta (A13 dopamine cell group) and the arcuate nucleus (A12 dopamine cell group) in IGF-I 
treated mothers. Without IGF-I, however, TH mRNA levels are low in the arcuate nucleus and are abundant 
in the zona incerta. (c,d) High magnification bright-field photomicrographs show the corresponding framed 
areas – the dorsomedial subdivision of the arcuate nucleus – in A and B to demonstrate increased density of 
individual autoradiography grains (black dots) in IGF-I-treated mothers. (e) Quantification of the signal in TH 
in situ hybridization histochemistry. The intensity in the arcuate nuclei of IGF-I treated mothers exhibited an 
approximate twofold increased compared with that in the ACSF-treated group (n = 6–6, *p < 0.05, p = 0.0435), 
while a significant difference was not detected in the zona incerta. The results are presented as the mean 
values ± SEM. Abbreviations: Arc – arcuate nucleus, A12–A13 – dopamine cell groups in the arcuate nucleus, 
and the zona incerta, respectively, 3 V – third ventricle. Scale bar = 1 mm for A and B and 100 µm for C and D.
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IGFBP-3. Since moving the pups into the nest is the most frequently used indicator of maternal motivation as 
a goal-directed behaviour35, our results suggest that elevated expression of IGFBP-3 in the MPOA in lactating 
dams contributes to maternal motivation. Different factors are known to contribute to the initiation and mainte-
nance of maternal behaviour. While peripartum hormonal changes initiate and potentiate the onset of maternal 
motivation, they are not required for maintenance of maternal care. Continuous exposure to pups and afferent 
stimuli from them are sufficient for supporting the maintenance of maternal motivation during the postpartum 
period15. The neurochemical regulatory mechanisms, which contribute to ongoing maternal care, are much less 
established. Based on our results, IGF-I and IGFBP-3 appear to contribute to the maintenance of maternal behav-
iours, thereby suggesting a previously unknown mechanism involved in maternal regulations. The lack of effects 
of prolonged IGF-I and NBI-31772 on activity in the elevated plus-maze test indicates that reduced maternal 
motivation was not a consequence of altered state of anxiety, which itself could affect maternal behaviour.
Based on the induction of IGFBP-3 in TH neurons of the arcuate nucleus, we also addressed its role in lac-
tation. In rodent mothers, lactation is driven by the suckling pup stimuli, which evokes a dramatic increase in 
serum prolactin levels46. We observed a high degree of elevation in control mothers, which received ACSF injec-
tion. However, prolactin levels increased to a significantly lesser degree after the sequestration of IGFBP-3, sup-
porting a role of IGFBP-3 in the regulation of prolactin secretion. Since prolactin increased significantly even in 
the presence of IGF-I in response to suckling, it is not possible to determine if a higher concentration of IGF-I 
could have blocked it completely or if prolactin has an IGF-I-independent component. At the same time, as 
prolactin levels were reduced in the presence of IGF-I, the body weight of pups gained during 1 hour of suckling 
was also decreased in the IGF-I group compared with that in the controls. These are new findings as hypotha-
lamic IGF-I and IGFBP-3 have not been shown to control prolactin secretion in mothers. Previous studies have 
revealed that IGF-I acts on lactation at the level of the pituitary by supporting the differentiation and proliferation 
of lactotroph cells47, 48. The involvement of hypothalamic IGF-I in reproductive neuroendocrine functions has 
been suggested before; it plays a role in the regulation of gonadotropin-releasing hormone (GnRH) cell function. 
Infusion of IGF-1 stimulated secretion of GnRH32, 49, while its antagonism impaired oestradiol-positive feedback 
and luteinizing hormone (LH) surges31, 33.
Binding of IGF-I to its receptor results in autophosphorylation of the receptor, which in turn initiates a cascade 
of cellular signal transduction events. One key step is the binding of insulin receptor substrate (IRS)-1 to phos-
photyrosine residues on the receptor. IRS-1 then acts as a docking protein for the downstream signal transduction 
components, including the Ras/ERK1/2 and PI3K/Akt pathways. IGF-I supports the survival of dopaminergic neu-
rons through these two pathways, which has mostly been investigated in the nigrostriatal dopamine system45, 50–52. 
IGF-I gene therapy in female rats reversed their hypothalamic DA dysfunction and hyperprolactinemia53. In line 
with these data, IGF-I enhanced TH expression in our hypothalamic cell culture experiments and in lactating 
rat dams. In dopaminergic neurons, activated ERK1/2 proteins enhance the transcriptional activation of TH by 
nuclear receptor related-1 (Nurr1)54, 55, which therefore represents a possible mechanism of the effect of IGF-I 
on TIDA neurons in our study. In addition, we also found an increase in the level of phosphorylation of the TH 
Figure 7. IGF-I treatment enhances the expression of TH and its phosphorylation on phosphorylation site Ser 
31 in primary mediobasal hypothalamic cell cultures. (a) The TH mRNA expression was approximately fourfold 
higher in cell cultures treated with IGF-I (12.5 µg/ml) for 4 days compared with that in controls (p = 0.048). 
Data are expressed as the ratio of GAPDH mRNA levels (n = 4 in both groups). (b) Following incubation with 
or without IGF-I (12.5 µg/ml) for 30 min, the cells were lysed, and the phosphorylation of TH at the Ser 31 and 
40 residues was determined using phosphorylation site-specific antibodies. Data are expressed as the ratio 
of TH intensity. The panels beside the diagram show representative images of immunoblot bands. Western 
blot results show that IGF-I treatment significantly increased the phosphorylation of TH at the Ser 31 residue 
(p = 0.003). There was no difference between the two cultures at the Ser 40 phosphorylation site (n = 6 for both 
groups). The results are presented as the mean values ± SEM.
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enzyme at the Ser 31 phosphorylation site by IGF-I in vitro. This finding suggests rapid enhancement of dopa-
mine synthesis by IGF-I as phosphorylation of TH results in an increased catecholamine production56. This rapid 
action of IGF-I on dopaminergic neurons has not been previously described. Rat TH can be phosphorylated at the 
four following different sites: Ser 8, 19, 31, 40, among which IGF-I action is selective for site 31 over 40. ERK1/2 
serine kinases are mainly responsible for Ser 31 phosphorylation57, suggesting that IGF-I may have acted via 
ERK1/2 serine kinases to induce phosphorylation of TH.
To exert these actions, IGF-I is present in the hypothalamic extracellular space at a relatively high concen-
tration58. IGF-I in this region could originate in neurons, which express IGF-I in the hypothalamus59, and in the 
circulation as IGF-I can reach the hypothalamus by crossing the blood-brain-barrier or blood-cerebrospinal fluid 
barrier60. IGF-I in the plasma shows decreased levels during pregnancy because of reduced growth hormone 
(GH) receptor expression in the liver. After delivery, circulating IGF-I reaches its original, higher levels61. The 
suckling stimulus is known to cause a rapid and transient increase in plasma GH62 but does not result in any sig-
nificant difference between lactating and pup-deprived animals61. These data suggest that the IGF-I concentration 
in the hypothalamus does not differ between lactating, pup-deprived mothers and virgin females, so its effects 
must be modified by other mechanisms that alter its concentration.
The elevated expression of IGFBP-3 could play an important role in decreasing effective IGF-I levels in the 
brain extracellular space by binding to IGF-I and neutralizing it. This mechanism has been suggested to underlie 
the effect of IGF-I on tau phosphorylation in Alzheimer’s disease; amyloid-β stimulates local astrocytes to release 
IGFBP-3, which in turn inhibits IGF-I-mediated suppression of tau phosphorylation63. We propose a similar 
mechanism in mother rats based on the existence of intrinsic IGF-I and IGFBP-3, which compose a system to 
regulate maternal changes in the brain (Fig. 8). In this model, IGF-1 inhibits maternal responses, and during the 
peri- and postpartum periods, the elevated expression of IGFBP-3 leads to the elimination of the inhibitory effects 
of IGF-I (Fig. 8). Since IGFBP-3 is expressed in TIDA neurons and probably in MCH neurons of the preoptic area, 
Figure 8. A model showing how the IGF-I - IGFBP-3 system regulates maternal responsiveness and prolactin 
release. (a) In virgin females and pup-deprived mothers, IGF-I of hypothalamic origin or from the circulation 
probably induce the expression of MCH in the preoptic area and enhances the expression of the TH enzyme, 
furthermore stimulates its activation by phosphorylation in TIDA neurons. Consequently, these cells produce 
more MCH or dopamine, which inhibits maternal responsiveness or prolactin secretion from the pituitary. 
(b) In lactating mothers, MCH and TIDA neurons enhance the expression of IGFBP-3, which can neutralize 
IGF-I. The MCH or TIDA stimulating effect induced by IGF-I diminishes, which results in a decrease in MCH 
or dopamine production and concomitant increased maternal responsiveness or prolactin secretion due to its 
release from tonic inhibition. Abbreviations: ac – anterior commissure, Arc – arcuate nucleus, f – fornix, MPA – 
medial preoptic area, och – optic chiasm, 3 V – third ventricle.
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IGFBP-3 can be released specifically from these cells in lactating dams to prevent the stimulatory action of IGF-I 
on these cells.
The regulation of the actions of a hypothalamic hormone by its binding proteins has also been previously 
suggested in other systems. For example, the corticosteroid-binding globulin expressed in the brain can direct 
the action of the stress hormone64, 65. The central distribution of sexual hormone-binding globulin (SHBG) is also 
known66. In the hypothalamus, SHBG expression shows alterations according to the reproductive state, so it may 
play role in modulating the central actions of ovarian steroids67. However, we also established state-dependent 
induction of IGFBP-3 to regulate the actions of IGF-I actions on these steroids. This hypothesis represents a novel 
mechanism in neuroendocrinology; neurons can block the effects of a hormone by inducing the expression of its 
binding protein. Nevertheless, the recently suggested role of IGF-independent effects of IGFBP-321–23 in maternal 
brain alterations cannot be excluded.
In conclusion, the major finding of this study is that prolonged IGF-I treatment reduced suckling-induced pro-
lactin release and maternal responsiveness. In turn, IGFBP-3 expression shows marked elevation in well-defined 
regions of the maternal brain, including the MPOA and the arcuate nucleus. The role of this elevated IGFBP-3 
may be the neutralization of the effect of IGF-I on distinct neurons by binding and sequestering it. Preventing the 
binding of IGFBP-3 to IGF-I with the ligand inhibitor NBI-31772 significantly suppressed maternal motivation. 
In addition, IGF-I also inhibited suckling-induced prolactin release. IGF-I can exert this action by increasing the 
dopamine release of TIDA neurons as IGF-I stimulated TH expression and phosphorylation. IGFBP-3 can reduce 
this action of IGF-I as TIDA neurons in the arcuate nucleus expressed a markedly elevated level of IGFBP-3 in 
lactating mothers. Thus, IGFBP-3 functions as an intrinsic regulator of lactation by switching TIDA neurons to 
a mode that permits induction of PRL release from the pituitary. Therefore, the IGF-I - IGFBP-3 systems can 
play an important role in the different aspects of the adaptation of the female brain to motherhood by a novel 
neuroendocrine mechanism.
Methods
Animals. All animal experimentations were approved by the Animal Examination Ethical Council of the 
Animal Protection Advisory Board at the Semmelweis University, Budapest, and met the guidelines of the Animal 
Hygiene and Food Control Department, Ministry of Agriculture, Hungary. A total of 85 female Wistar rats 
(250–300 g adult body weight; Charles Rivers Laboratories, Budapest, Hungary) were used in this study (Table 3). 
Animals were kept on standard laboratory conditions with 12-h light, 12-h dark periods (lights on at 06:30), and 
supplied with dry rat food and drinking water ad libitum. Rats were housed three per cage at a temperature of 
22 ± 1 °C before experiments. For mating, two female and a male rat were kept in a cage for 7 days. After that, 
potentially pregnant female rats as well as dams with litter and their pup-deprived counterparts were kept in cages 
individually. Rats were anesthetized between 9 and 10 AM with an intramuscular injection of anaesthetic mix 
containing 0.3 mL/300 g body weight ketamine (67 mg/kg) and 0.2 mL/300 g body weight xylazine (13 mg/kg) 
before implantation of osmotic minipumps or jugular cannulae, decapitation and cardiac perfusion.
Objective Number of rats
Postpartum 
day Experimental procedure
Measurement of IGFBP-3 
mRNA level
9 lactating mothers vs. 8 
pup-deprived mothers 11
th day RT-PCR
Establishment of the 
expression pattern and 
level of IGFBP-3
6 lactating mothers vs. 6 
pup-deprived mothers 11
th day In situ hybridization histochemistry (ISHH)
Examination of the 
expression of IGFBP-3 in 
dopaminergic neurons
5 lactating mothers 11th day
Combination of ISHH 
for IGFBP-3 and 
immunohistochemistry for TH
Determination of the 
role of IGF-I system in 
maternal behaviour and 
TH expression level
10 IGF-I-treated vs. 10 
ACSF-treated, and 8 
NBI-31772-treated vs. 
8 DMSO-ACSF-treated 
(control) lactating 
mothers
2nd day Implantation of osmotic minipumps
6th day Pup-retrieval test
7th day Elevated plus-maze test
4–9th days Examination of undisturbed maternal behaviour
4 IGF-I-treated vs. 4 
ACSF-treated lactating 
mothers
14th day In situ hybridization histochemistry
Determination of the 
role of IGF-I system in 
prolactin release
7 IGF-I-treated vs. 8 
ACSF-treated (control) 
lactating mothers
2nd day Implantation of osmotic minipumps
13th day Implantation of jugular cannulae
14th day Blood sampling for prolactin measurement
Table 3. Summary and timing of the experiments with specification of the number of used animals in each 
experiment.
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Microdissection of brain tissue samples. On the 11th day postpartum, brains were dissected from 9 
primiparous lactating and 8 pup-deprived rat dams. Thick coronal brain sections were prepared around the pre-
optic area with a razor blade cut immediately rostral to the optic chiasm and 2 mm caudal to this level (Fig. 2a). 
A horizontal cut immediately above the anterior commissure, and sagittal cuts on both sides of the brain 2  mm 
lateral to the midline were used to dissect tissue. Dissected area contained the preoptic area of the hypothalamus 
as well as small parts of adjacent brain structures including parts of the diagonal band of Broca, the anterior com-
missure, the optic tract, the ventral pallidum. In this study, however, we refer to this tissue block as the preoptic 
area. The dissected tissue samples were quickly frozen on dry ice, and stored at −80 °C.
Real-time RT-PCR. Real-time RT-PCR was carried out as described previously16. Briefly, Total RNA was 
isolated from frozen preoptic tissue samples, or lysated primer cultures. The concentration of RNA was adjusted 
to 2 µg/µL, and it was treated with Amplification Grade DNase I (Invitrogen). Then, cDNA was synthesized 
using SupersciptII (Invitrogen) as suggested in the kit protocol. The cDNA was subsequently diluted (10x), and 
2.5 µL of the resulting cDNA was used as template in PCR reactions using SYBR Green dye (Sigma, St Louis, 
MO, USA). The PCR reactions were performed with iTaq DNA polymerase (Bio-Rad Laboratories, Hercules, 
CA, USA) and GAPDH was used as housekeeping gene. The primers were: ACAGCCAGCGCTACAAAGTT 
an d  G C G G TAT C TAC T G G C TC TG C  for  IG F B P- 3 ,  an d  G C TAC C G AG AG G AC AG C AT C 
a n d  G C AC C ATA AG C C T T C AG C T C  f or  T H ,  a n d  T G C C AC T C AG A AG AC T G T G G  a n d 
GTCCTCAGTGTAGCCCAGGA for GAPDH. Cycle threshold (Ct) values were obtained from the linear region 
of baseline adjusted amplification curves. The GAPDH related values were calculated using the following formula: 
log(Ct(GAPDH) − Ct(IGFBP3 or TH)). Statistical analyses were performed by unpaired t-test for comparisons of the two 
different groups.
Production of in situ hybridization probe for IGFBP-3 and TH. Preparation of the in situ hybrid-
ization probes was performed as described previously68. Briefly, PCR products of amplification of IGFBP-3 
and TH were produced from hypothalamic cDNA using the following primer pairs for IGFBP-3: A: 
ACAGCCAGCGCTACAAAGTT and GCGGTATCTACTGGCTCTGC, B: CCTTGTTGGAGACCCTGGTA 
and TCACACCCTGTATTGCCAGA; and the following for TH: GCTACCGAGAGGACAGCATC and 
GCACCATAAGCCTTCAGCTC. The PCR products were purified from gel, inserted into TOPO TA cloning 
vectors (Life Technologies) and transformed chemically into competent bacteria. Selected plasmids were applied 
as templates in PCR reactions, using the primer pairs specific for IGFBP-3 and TH, respectively, with the reverse 
primers also containing a T7 RNA polymerase recognition site. At the end, the identities of the cDNA probes were 
verified by sequencing.
In situ hybridization histochemistry. To describe the expression pattern of IGFBP-3 and also to measure 
the expression level of IGFBP-3, brains of 6 primiparous lactating mothers and 6 age-matched pup-deprived 
mothers were removed at 11 days postpartum. In addition, brains of 4 IGF-I and 4 ACSF-treated rat mothers were 
removed at the end of the treatment, at 14 days postpartum to examine the effects of prolonged i.c.v. IGF-I admin-
istration on TH expression levels. The fresh tissue was quickly frozen on dry ice. In situ hybridization histochem-
istry was processed as described previously16. Briefly, serial coronal sections (12 µm) were cut using a cryostat 
from bregma level + 3.5 mm to −6 mm, mounted on positively charged slides (SuperfrostUltraPlus™; Thermo 
Fisher Scientific, Pittsburgh, PA, USA), dried, and stored at −80 °C until use. Antisense [35 S]UTP-labelled ribo-
probes were generated using T7 RNA polymerase of the MAXIscript In vitro transcription kit (Ambion, Austin, 
TX) from PCR-amplified fragments of the cDNA subcloned into TOPO TA vectors. Tissue was prepared using an 
mRNA-locator Kit (Ambion) according to manufacturer’s instructions. For hybridization, we used 80 µl hybrid-
ization buffer and 1 million DPM of labelled probe per slide. Washing procedures included a 30 min incubation 
in RNase A, followed by decreasing concentrations of sodium-citrate buffer (pH = 7.4) at room temperature, 
and then at 65 °C. After drying, slides were dipped in NTB nuclear track emulsion (Eastman Kodak, Rochester, 
NY), stored for 3 weeks at 4 °C for autoradiography. Then, the slides were developed and fixed with Kodak Dektol 
developer and Kodak fixer, respectively, counterstained with Giemsa, dehydrated, and coverslipped.
Densitometric analysis of in situ hybridization histochemistry signal. Dark-field photomicro-
graphs were taken of the sections where IGFBP-3 and TH signal was the highest in the medial preoptic area, and 
arcuate nucleus and zona incerta, respectively, using a 10x objective. Each image was divided into 2 halves with 
identical size, such that one half contained the observed autoradiography signals, while the other half served as 
background control. The pixel number of these areas was calculated using ImageJ 1.47 v (National Institutes of 
Health, USA) software. The difference between the 2 values (the half picture containing labeled cells - the half 
picture containing only background autoradiography signal) was used to quantify IGFBP-3 and TH mRNA levels. 
mRNA levels in the 2 groups were compared using two-tailed unpaired t-test.
Implantation of intracerebroventricular cannulae. On the 2nd day postpartum, rats were divided into 
4 groups to determine the role of IGF-I system in maternal behaviour and TH expression level: icv. infusion of 
ACSF (n = 10), IGF-I dissolved in ACSF (n = 10), 1% DMSO in ACSF (n = 8), NBI-31772 (n = 8) dissolved in 
ACSF containing 1% Dimethyl sulfoxide (DMSO). In another experiment, 7 IGF-I-treated vs. 8 ACSF-treated 
(control) mothers were used to determine the role of IGF-I system in prolactin release. Osmotic minipumps 
injecting continuously for 14 days (ALZET Micro-Osmotic Pump Model 2002, Durect™) were used loaded with 
IGF-I (4 µg/µl; 48 µg IGF-I/day, PeptideSciences™), NBI-31772 (1.66 µg/µl; 19,92 µg NBI-31772/day, Merck™), 
ACSF (147 mM NaCl, 3.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, pH = 7.2), or 1%DMSO in ACSF connected to 
cannulae according to manufacturer’s guide. For intracerebroventricular (i.c.v.) implantation of the cannulae, rats 
were anesthetized with 0.2 ml xylazine and 0.3 ml ketamine and fixed in a stereotaxic apparatus. The skin was cut 
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over the skull and a hole of about 1 mm diameter was drilled into the left side of the skull above the lateral ventri-
cle positioned at the following coordinates: antero-posterior, −0.5; lateral, 1.4; ventral, 3.6 mm. Cannulae (ALZET 
Brain Infusion Kit 2, Durect™) were inserted into the lateral ventricle and fixed to the skull with cranioplastic 
cement and the pumps placed subcutaneously (s.c.) at the back of the animal. After the operation, Tardomyocel® 
comp. III antibiotics (0.1 ml/kg body weight) was given s.c. to the animals for 5 days to prevent infections.
Undisturbed maternal behaviour. We used 36 mother rats injected i.c.v. with osmotic minipumps to 
investigate their undisturbed maternal behaviour. The behaviour of each dam was recorded as described previ-
ously69. Briefly, the undisturbed maternal behaviour was observed for three 60 min daily observation periods, 
5 days long, starting on 4th day postpartum, after one day recovery following the implantation of osmotic min-
ipumps. Observations were performed at two periods during the light phase (8:00 and 13:00 h, lights ON at 06:30) 
and at one period during the dark phase (19:30 h, lights OFF at 18:30). Within each observation period, the 
behaviour of each mother was scored 20 times spaced 3 min each one (20 observations × 3 periods per day × 5 
days = 300 observations/mother) as present or absent. The following behaviours were scored as present or absent: 
high kyphosis (HK): mother nursing pups in an arched-back posture with rigid limbs; licking/grooming (LG): 
mother licking–grooming any pup (body + anogenital region); prone nursing (PN): mother nursing in a “blan-
ket” posture in which the mother just lies over the pups, but did not have her back arched and there was no obvi-
ous extension of her legs; supine nursing (SN): mother nursing in a “passive” posture in which the mother lies 
on her back or side while the pups are nursed; out of the nest (0): mother out of the nest (no maternal contact). 
Number of each behaviour/300 observation ratio was calculated for every mother. Normality was tested with 
Kolmogorov-Smirnov test while difference of the mean was analyzed with unpaired two-tailed t-test.
Pup retrieval test. We used 36 mother rats injected i.c.v. with osmotic minipumps for testing. On postnatal 
day 6, all pups were separated from their mothers for 10 min. Subsequently, 3 pups were returned to the mother’s 
cage in 3 different corners of the cage away from the nest. The mother was visually observed for 5 min. The time 
required for the mother to carry the first and the third pup to the nest was recorded. Normality was tested with 
Kolmogorov-Smirnov test. Results were analyzed with two-tailed Mann-Whitney-, or unpaired t-test with Welch 
correction.
Elevated plus-maze test (EPM). To measure anxiety, dams were exposed to EPM on postnatal day 7 
during the afternoon. The EPM was made of plastic, painted black and elevated 80 cm above the floor (arm 
length 50 cm; arm width 15 cm; central platform 15 × 15 cm; closed arm walls height 70 cm). Surface of maze 
was washed with water, alcohol and dried before the next animal was introduced. The duration of the test was 
5 min. Rats were introduced in the centre of the maze facing a closed arm. Percentage of time spent in open arms 
and percentage of open arm entries (number of open arm entries/number of open plus closed arm entries) were 
calculated and used as measures of anxiety (entry: at least two third of the body in an arm). Normality was tested 
with Kolmogorov-Smirnov test while difference between the means was analyzed with two-tailed unpaired t-test.
Combination of in situ hybridization histochemistry and immunohistochemistry. Brains of 5 
lactating mother rats perfusion fixed on postpartum day 11 were used to examine the expression of IGFBP-3 
in dopaminergic neurons. In situ hybridization histochemistry was performed as described above except that 
20 mm thick sections were used. Following hybridization with IGFBP-3 probe and before dipping the sections in 
nuclear track emulsion, TH immunohistochemistry was carried out in humid chambers. Slides were first treated 
with mouse anti-TH antibody (dilution 1:1000; Chemicon, MAB5280), then in horse anti-mouse IgG (1:1000; 
Vector Laboratories™, Burlingame, CA, USA) for 1 h, then in ABC complex (1:500; Vector Laboratories™,) for 
2 h. Finally, the sections were visualized with 3,3-diaminobenzidine (DAB) reaction.
Microscopy and image processing. Sections were examined using an Olympus BX60 light microscope 
equipped with a dark-field condenser. Images were captured at 2048 × 2048 pixel resolution with a SPOT Xplorer 
digital CCD camera (Diagnostic Instruments, Sterling Heights, MI) using 4–40 X objectives. Images were 
adjusted using the “levels” and “sharpness” commands in Adobe Photoshop CS 8.0. Full resolution of the images 
was maintained until the final versions, which were adjusted to a resolution of 300 dpi.
Implantation of jugular cannulae. On the 13th postpartum day - under ketamine-xylazine anaesthesia 
(described above) – 15 dams (7 IGF-treated, 8 ACSF-treated) received 25-mm-long sterile polyethylene jugular can-
nulae (Plastics One). A ventral cervical skin incision was made right of the midline with its caudal terminus at the level 
of the clavicle. The right common jugular vein was mobilized, and cannulae were inserted into the vessel and secured 
in place with suture. Incisions were made on the skin at the midline between the scapulae, and jugular cannulae were 
pulled through the scapular incisions. The cannulae were filled with heparinized saline and sealed with metal pins.
Blood sampling before and during suckling. On the next day we obtained blood via jugular cannulae 
to measure serum prolactin levels induced by suckling: first before taking away the pups for 4 h, second before 
returning the pups (baseline control) and also 5, 15, 30, 60 min after the return. The volume of blood taken was 
0.3–0.3 ml each time, and the same amount of heparinized saline was injected back into the circulation. Blood was 
centrifuged at 4 °C for 10 min at 12.000 g and the supernatant was stored at −20 °C for measurement of prolactin 
plasma concentrations by radioimmunoassay.
Prolactin assay. Prolactin assay was performed as described previously70. Briefly, the chloramine-T method 
was used for iodination, and protein A (BactASorb, Human Rt, Gödöllő, Hungary) was used to separate bound 
and free hormone. LKB Clinigamma software was used for data collection and calculations for curve fitting. 
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Within-assay variance was 10%. Between-assay variance was 14%. The sensitivity of the prolactin assay was 
0.5 ng/ml rat plasma (or 25 pg prolactin). All samples were analyzed in duplicate using 50 ml of plasma for each 
measurement.
Statistical analysis of the prolactin assay. Statistical analyses were performed using Prism 5 for 
Windows (GraphPad Software, Inc., La Jolla, CA). Normality was tested with Kolmogorov-Smirnov test. For the 
suckling experiment, plasma prolactin levels of the 2 groups were compared using repeated measures two-way 
ANOVA to evaluate whether suckling and prolonged administration of IGF-I had an effect on the prolactin level. 
For posthoc comparisons, Newman-Keuls test were used.
Preparation of hypothalamic cell cultures. 10 pathogen-free newborn Wistar rats (Charles-River 
Laboratories) were decapitated right after birth and the mediobasal hypothalamus was excised. The tissue 
blocks were immediately transferred to an ice cold medium containing 2% B27, 49% Dulbecco’s modified Eagle’s 
medium, 49% F12 medium and penicillin-streptomycin (DMEM-F12-B27-P/S; Gibco®, Life Technologies™). 
First, tissue was homogenized and centrifuged for 4 min on 3000 rpm. Second, the supernatant was removed 
and 2 ml 0.1% Trypsin (diluted in DMEM) added to the pellet. Third, after 4 min incubation in a 37 °C water 
bath with Trypsin, 2 ml 0.5% DNase and 1% Bovine Serum Albumin (diluted in DMEM-P/S) was added to the 
digested tissue, mixed and centrifuged for 4 min at 3000 rpm. After this, supernatant was removed again, and 2 ml 
DMEM-F12-B27-P/S was put to the pellet, mixed and centrifuged for 4 min at 3000 rpm. This step was repeated 
twice and the resultant cell pellet was dispersed in DMEM-F12-B27-P/S at a density of approximately 3.9 × 105 
cells/ml and plated out at 0.5 ml/well onto 8 wells of a polylysine coated 24-well culture plate, which were then 
transferred to a 5% CO2 humidified incubator at 37 °C. After the first 24 h in culture, half of the medium (250 µl/
well) was removed and changed to 25 µg/ml IGF-I (PeptideSciences™, diluted in DMEM-F12-B27-P/S) in 4 wells 
and DMEM-F12-B27-P/S in other 4 wells, as controls. Half of the medium was replaced every day as described 
above and cells were used for examination on the 5th day.
Western blot analysis. After removal of the medium, cells were washed twice with sterile PB solution 
and then mixed with RIPA (1 M Na-orthovanadate, 1 M NaF, Triton X100, TNE buffer: Trisma base, EDTA, 
NaCl, pH = 7.4) + Protease Inhibitor (RIPA + ; 40 µl PI/1 ml RIPA) using a pipette tip. Cells were collected in 
RIPA + and centrifuged on 4 °C at 16000 rpm. Protein concentration was measured and equilibrated to 1 µg/µL. 
After that Laemmli sample buffer (1% bromophenol blue, 1.5 M Trisma base, 99.5% glicerol, sodium dodecyl 
sulphate salt, β-mercaphtoethanol) was added to the removed supernatant and heated at 90 °C for 5 min. After 
running the gels and transferring the proteins to membranes (0.45 µm polyvinylidene difluoride, Amersham™ 
Hybond™, Life Sciences), the membranes were treated with 3% BSA solution for 2 h. Then, primary antibodies 
were added to membranes for 24 h (1:1000; rabbit anti-phospho TH at Ser 31, SAB4300674, Sigma; 1:10000; 
rabbit anti-phospho TH at Ser 40, T9573, Sigma; 1:1000, rabbit anti-TH, AB152, Millipore; and 1:2000, mouse 
β-tubulin-III, T8578, Sigma) and secondary for 1 h (1:10000, peroxidase labelled goat anti-rabbit or anti-mouse 
IgG; Jackson Immuno Research). Membranes were treated with Clarity™ Western ECL Substrate (Bio-Rad) for 
chemiluminescence detection, which was performed with ChemiDoc™ MP Imaging System (Bio-Rad). Intensity 
of bands was calculated using ImageLab software (Bio-Rad). Ratio of phospho TH – TH intensity was calculated 
using the following formula: (phospho TH intensity/-tubulin-III intensity)/(TH intensity/β-tubulin-III intensity) 
and analysed with two-tailed unpaired t-test.
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